Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;127(2):275-281.
doi: 10.1002/jso.27166.

The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Nathaniel Deboever  1 , Michael Eisenberg  1 , Alexis Chidi  1 , Boris Sepesi  1
Affiliations
Review

The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Nathaniel Deboever et al. J Surg Oncol. 2023 Feb.

Abstract

As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.

Keywords: immunotherapy; resectable nonsmall cell lung cancer; targeted therapy.

PubMed Disclaimer

References

REFERENCES

    1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554.
    1. Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current surgical indications for non-small-cell lung cancer. Cancers. 2022;14(5):1263.
    1. Shu CA, Cascone T. What is neo? Chemoimmunotherapy in the neoadjuvant setting for resectable non-small-cell lung cancer. J Clin Oncol. 2021;39(26):2855-2858.
    1. Anderson MD, Cancer Center. LCRF leader neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early stage lung cancers. PI: Boris Sepesi. Est Completion. 2023:NCT04712877.
    1. Steuer CE, Behera M, Berry L, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the lung cancer mutation consortium. Cancer. 2016;122(5):766-772.

MeSH terms